On September 9, 2020 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, SEP 9, 2020, View Source [SID1234564880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Virtual Global Healthcare Conference on Tuesday, September 15 at 1:20 PM Eastern Time. To view the presentation live, please go to View Source The presentation will be archived there for 90 days. For more information about the Cantor Virtual Global Healthcare Conference, please refer to the conference website at View Source

Lake Street Capital Market’s 4th Annual Best Ideas Growth (BIG4) Conference on September 17, with one-on-one and group meetings throughout the day. For more information about the 4th Annual BIG4 Conference, please refer to the conference website at View Source
For further information regarding Soligenix, Inc., please visit the Company’s website at www.soligenix.com.